PTGS2–899G>C and prostate cancer risk: a population-based nested case–control study (ProtecT) and a systematic review with meta-analysis
PTGS2–899G>C and prostate cancer risk: a population-based nested case–control study (ProtecT) and a systematic review with meta-analysis
复制标题
PTGS2–899G>C 和前列腺癌风险：基于人群的巢式病例对照研究 (ProtecT) 和荟萃分析系统评价
DOI：
--
复制
发表时间：
2009
影响因子：
4.8
通讯作者：
R. Martin
中科院分区：
文献类型：
--
作者：
Ali S. Murad;Sarah J Lewis;George Davey Smith;Simon M Collin;Lina Chen;F. Hamdy;D. Neal;J. Donovan;R. Martin
前列腺素内过氧化物酶合酶2是炎症的关键调节因子，并可能在前列腺癌发生中发挥作用。多态性，-899G>C（rs 20417），改变了转录因子结合位点，并与结直肠腺瘤的风险降低有关。我们使用一项大型病例对照研究（ncases=1608，ncontrols=3058）检验了rs 20417可能影响前列腺癌风险的假设。我们没有发现rs 20417改变前列腺癌风险的证据（比值比（ORCC & GC vGG =1.05，95%置信区间（CI）=0.91-1.20）。对三项研究的荟萃分析也发现，几乎没有证据表明rs 20417改变了风险（合并ORCC和GC v GG=1.04，95%CI =0.93-1.17），因此rs 20417不太可能以任何主要方式对前列腺癌病因学做出贡献。
Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, –899G>C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case–control study (ncases=1608, ncontrols=3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (ORCC & GC v GG=1.05, 95% confidence interval (CI)=0.91–1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled ORCC & GC v GG=1.04, 95% CI=0.93–1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.
影响因子：
158.5
作者：
Lichtenstein, P;Holm, NV;Hemminki, K
通讯作者：
Hemminki, K